We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Justine
Kane
Justine.kane@addenbrookes.nhs.uk
Deborah
Whitehorn
Deborah.whitehorn@addenbrookes.nhs.uk
Victoria
Theobalf
Victoria.Theobald@addenbrookes.nhs.uk
Jean
Abraham
ja344@medschl.cam.ac.uk
Jo
Worley
joanna.worley1@nhs.net
Jonathan
Lay
jonathan.lay2@nhs.net
Malignant neoplasm of breast
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
PBCP will sequence the healthy genome (DNA and RNA) of 2000 patients diagnosed with breast cancer as well as the genome of their tumour, in order to learn how to adapt cancer treatment by looking at the genome of the tumour.
The aims of this program are to facilitate new discoveries that will help us understand why some people are cured of their cancer, and others are not. It will also contribute to improving our understanding of why some people experience more side-effects than others. It will support clinicians and researchers to develop new therapies and diagnostic tests, and it will also help the NHS to develop genomic medicine to benefit cancer patients.
The PBCP will assess the role of Whole Genome Sequencing (WGS) and RNA sequencing (RNAseq) in the clinical management of breast cancer patients. To do this, the PBCP will examine the genomes of patients with breast cancer and return the results of the sequencing, which are relevant to breast cancer or its treatment, to a patient within 12 weeks. As part of this program, we will collect blood and tissue samples from patients at various time points so that we can produce genetic “fingerprints” from the breast cancer, which we can then analyse and compare using a variety of laboratory techniques.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Presence of any psychological or social reasons potentially hampering compliance with study protocol and follow-up schedule.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Jo
Worley
joanna.worley1@nhs.net
Victoria
Theobalf
Victoria.Theobald@addenbrookes.nhs.uk
Deborah
Whitehorn
Deborah.whitehorn@addenbrookes.nhs.uk
Jonathan
Lay
jonathan.lay2@nhs.net
Jean
Abraham
ja344@medschl.cam.ac.uk
Justine
Kane
Justine.kane@addenbrookes.nhs.uk
The study is sponsored by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST and funded by CANCER RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 39296
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
